上海证券交易所文件 ─────────────── 上证上审（再融资）〔2023〕601 号 关于江苏吴中医药发展股份有限公司向特定 对象发行股票申请文件的审核问询函 江苏吴中医药发展股份有限公司、中山证券有限责任公司： 根据《证券法》《上市公司证券发行注册管理办法》《上海 证券交易所上市公司证券发行上市审核规则》等有关法律、法规 及本所有关规定等，本所审核机构对江苏吴中医药发展股份有限 公司（以下简称发行人或公司）向特定对象发行股票申请文件进 行了审核，并形成了首轮问询问题。 1.关于本次募投项目必要性 根据申报材料，1）江苏吴中医药集团研发及产业化基地一 期项目将进一步扩大现有产品的生产规模并增加其他产品的生 1 产线，为公司现有在研产品与未来新药研发提供研发与生产基地， 为制药公司和新药研发公司客户提供从临床前到商业化的研发 生产一体化服务，完善公司在 CDMO 业务的产业布局。2）报告 期内，公司主营业务以医药业务为主，贸易业务为辅，医药业务 可分为医药工业和医药商业，医药工业指发行人自营产品的生产 经营，医药商业指医药配送业务。3）本项目建成后，苏药厂将 停产，现有产品迁移至本项目生产。 请发行人说 ...

证券代码：600200 证券简称：江苏吴中 公告编号：临 2023-039 江苏吴中医药发展股份有限公司 关于参加沪市主板生物医药行业上市公司2022年年报集体 业绩说明会暨2023年第一季度业绩说明会的公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 重要内容提示： 投资者可于 2023 年 05 月 05 日（星期五）至 05 月 11 日（星期四）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 lirui@600200.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 江苏吴中医药发展股份有限公司（以下简称"公司"）于 2023 年 4 月 27 日披露了公司 2022 年度报告及 2023 年第一季度报告，为便于广大投资者更全面 深入地了解公司 2022 年度及 2023 年一季度经营成果、财务状况，同时更加充分 地向投资者展示生物医药行业发展情况，公司计划于 2023 年 5 月 12 日下午 15:00-16:00 参加沪市主板生物医药行业上市公司 2022 年年报集体 ...

Financial Performance - In 2022, the company achieved a consolidated net profit attributable to shareholders of -76,197,270.30 CNY, a decrease of 435.43% compared to the previous year's profit of 22,716,282.29 CNY[5]. - The company's operating income for 2022 was 2,026,232,836.21 CNY, representing a year-on-year increase of 14.12% from 1,775,450,710.11 CNY in 2021[21]. - The net cash flow from operating activities was 56,273,913.03 CNY, a significant decrease of 87.43% compared to 447,643,667.01 CNY in the previous year[21]. - The company's net assets attributable to shareholders decreased by 2.77% to 1,803,693,253.17 CNY at the end of 2022, down from 1,855,013,445.80 CNY in 2021[21]. - The company reported a net profit attributable to shareholders after deducting non-recurring gains and losses of -96,516,313.05 CNY in 2022, compared to -87,969,266.96 CNY in 2021[21]. - The company reported a net profit attributable to the parent company of CNY -76,197,300.00, indicating a loss[75]. - The gross profit reached CNY 579,661,500.00, reflecting a 13.23% increase year-over-year[75]. - The total revenue for the company was CNY 67,219.24 million, reflecting a year-on-year increase of 9.73%[113]. Strategic Developments - The company does not plan to distribute profits or increase capital reserves for the fiscal year 2022 due to the negative net profit[5]. - The company has acknowledged the presence of industry risks that may impact future development, as detailed in the management discussion section[8]. - The company’s future plans and strategic developments are subject to investment risks, and no substantial commitments have been made to investors[6]. - The company is actively exploring equity cooperation models and expanding its CDMO business in small molecule and biologics sectors[34]. - The company is committed to enhancing its internal controls and exploring innovative sales models to adapt to new industry policies and market dynamics[104]. - The company is focusing on high-end generic drugs and the consistency evaluation of existing products in its R&D strategy[116]. - The company is committed to enhancing its research and development capabilities to drive innovation in the pharmaceutical sector[109]. Research and Development - The company optimized its R&D management structure, establishing a comprehensive management system for pharmaceutical R&D with dedicated research institutes for innovative drugs and generics[33]. - The company has established a comprehensive product layout in key therapeutic areas, including antiviral, anti-tumor, and immunomodulatory drugs, enhancing its competitive edge[103]. - The company is focusing on the development of new drugs for gastrointestinal and respiratory diseases, with multiple patents filed in recent years[109]. - The company has ongoing research and development projects, with a focus on new drug development and consistency evaluation for existing products[123]. - The company’s R&D investment for the reporting period amounted to RMB 44,851.60 million, with a capitalization ratio of 39.80%[125]. - The major R&D projects included a respiratory system traditional Chinese medicine project with an investment of RMB 32.74 million and an anti-tumor project with RMB 370.87 million, where RMB 328.87 million was capitalized[126]. Market Trends and Industry Insights - The pharmaceutical manufacturing industry in China reported a cumulative revenue of CNY 2,911.14 billion in 2022, with a year-on-year growth rate of -1.60%[42]. - The chemical pharmaceutical industry remains a dominant segment in the Chinese market, driven by increasing healthcare demands and an aging population[45]. - The overall medical aesthetics market is experiencing a shift towards non-surgical treatments, which are preferred by consumers due to lower risks and shorter recovery times[46]. - The market size for hyaluronic acid-based dermal fillers in China was RMB 6.4 billion in 2021, with a CAGR of 19.7% from 2017 to 2021, and is projected to reach RMB 19.6 billion by 2026, reflecting a CAGR of 25.0% from 2021 to 2026[47]. - The market for recombinant collagen-based functional skincare products is forecasted to reach RMB 64.5 billion by 2027, with a CAGR of 55.0% from 2022 to 2027[52]. Regulatory Environment - In 2022, over 320 new policies related to the pharmaceutical industry were introduced, indicating a significant regulatory shift that may impact market dynamics[54]. - The Chinese government is focusing on enhancing the medical and pharmaceutical sectors through various strategic plans, emphasizing innovation and quality assurance[55]. - The National Medical Products Administration (NMPA) has initiated a public consultation on the draft regulations for the implementation of the Drug Administration Law, encouraging the development of drugs for rare diseases and children's medications[59]. - The NMPA's new regulations on drug registration aim to enhance the management of chemical raw materials and improve the drug approval process, reflecting the government's commitment to streamline regulations[60]. Corporate Governance and Management - The company has a well-defined corporate governance structure that complies with relevant laws and regulations, ensuring effective checks and balances[162]. - The company emphasizes investor relations management, providing multiple channels for communication with investors[164]. - The company has implemented a stock incentive plan and an employee stock ownership plan, which were approved in the shareholder meetings[166][167]. - The company held five board meetings in 2022, with two conducted in person and three via communication methods[185]. - The company has established a "Major Event Reporting System" to ensure timely reporting of significant events from subsidiaries to enhance decision-making efficiency and risk management[198]. Human Resources and Talent Development - The company has implemented a wide salary policy based on job responsibilities and performance, ensuring competitive compensation and benefits[193]. - The company emphasizes talent development through a three-tier training program, including new employee training and leadership development[194]. - The company’s executive compensation is directly linked to performance and responsibilities, enhancing the effectiveness of its incentive mechanisms[197]. - The employee composition includes 329 production personnel, 251 sales personnel, 176 technical personnel, 38 financial personnel, and 215 administrative personnel[192].

Financial Performance - The company's operating revenue for Q1 2023 was CNY 611,782,589.11, representing a year-on-year increase of 37.69%[5] - The net profit attributable to shareholders of the listed company reached CNY 28,152,696.06, a significant increase of 269.61% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 5,984,226.17, up by 67.86% year-on-year[5] - The company's basic earnings per share for Q1 2023 was CNY 0.040, an increase of 259.29% year-on-year[5] - Net profit for Q1 2023 was RMB 27,581,716.49, compared to RMB 7,016,937.24 in Q1 2022, reflecting a significant increase of approximately 292.5%[19] - The total comprehensive income for Q1 2023 was ¥27,357,334.45, up from ¥7,160,392.95 in Q1 2022[20] - Basic and diluted earnings per share for Q1 2023 were both ¥0.04, compared to ¥0.01 in Q1 2022, indicating improved profitability[20] Assets and Liabilities - The total assets at the end of Q1 2023 were CNY 4,014,492,239.99, reflecting a 2.68% increase from the end of the previous year[6] - The company's total assets as of March 31, 2023, amounted to RMB 4,014,492,239.99, compared to RMB 3,909,731,794.92 at the end of 2022, showing a growth of about 2.7%[16] - Current assets totaled RMB 2,833,932,137.70 as of March 31, 2023, an increase from RMB 2,729,547,553.76 at the end of 2022, representing a growth of approximately 3.8%[14] - Current liabilities increased to RMB 1,965,843,729.82 as of March 31, 2023, from RMB 1,855,556,809.51 at the end of 2022, indicating a rise of about 5.9%[16] - Long-term liabilities decreased to RMB 194,415,344.80 as of March 31, 2023, down from RMB 230,600,842.08 at the end of 2022, reflecting a decline of approximately 15.7%[16] - Total liabilities reached approximately $2.09 billion, with current liabilities at $1.86 billion and non-current liabilities at $230.6 million[27] - Shareholders' equity totaled approximately $1.82 billion, with a significant portion being capital reserves of $1.40 billion[28] Cash Flow - The net cash flow from operating activities was negative at CNY -80,312,170.27, a decline of 284.20% compared to the previous year[5][8] - Cash inflows from operating activities totaled ¥1,861,212,711.77 in Q1 2023, compared to ¥1,538,319,753.00 in Q1 2022, reflecting a growth of approximately 20.9%[22] - The net cash flow from operating activities was negative at -¥80,312,170.27 for Q1 2023, a decline from a positive ¥43,601,145.05 in Q1 2022[22] - Cash inflows from investment activities were ¥225,751,257.64 in Q1 2023, significantly higher than ¥86,880,669.00 in Q1 2022[23] - The net cash flow from financing activities for Q1 2023 was ¥148,902,129.12, compared to ¥123,207,093.37 in Q1 2022, showing an increase of approximately 20.9%[23] - The company reported a total cash inflow from financing activities of ¥696,259,829.84 in Q1 2023, compared to ¥572,340,828.62 in Q1 2022[23] Investment and Other Income - The company reported a significant increase in investment income of 708.20%, attributed to the transfer of equity in Changzheng Xinkai[7] - The company reported a significant increase in investment income, reaching RMB 23,655,227.13 in Q1 2023, compared to RMB 2,926,920.16 in Q1 2022, indicating a growth of approximately 707.5%[19] - The company has a long-term investment in equity amounting to approximately $426 million, showcasing its commitment to strategic investments[26] Other Financial Metrics - The weighted average return on equity increased by 1.14 percentage points to 1.55%[5] - The company experienced a 91.19% decrease in other current assets due to the redemption of financial products[7] - The construction of a new pharmaceutical base has led to a 71.35% increase in construction in progress[7] - The company experienced a decrease in other comprehensive income, with a net amount of -¥224,382.04 in Q1 2023, compared to ¥143,455.71 in Q1 2022[20] - The company reported a net loss of approximately $416.54 million, which is a slight improvement from the previous quarter[28] - The total amount of short-term borrowings was approximately $1.37 billion, indicating reliance on external financing[27] - The company has a deferred tax asset of approximately $2.75 million, which may provide future tax benefits[26]

Financial Performance - The company's operating revenue for Q3 2022 was ¥594,281,822.27, representing a year-on-year increase of 37.19%[7] - The net profit attributable to shareholders was -¥27,415,072.91, with a year-to-date net profit of -¥46,827,361.12, reflecting a decrease of 194.81% compared to the same period last year[7] - The basic earnings per share for the quarter was -¥0.039, a decrease of 195.27% year-on-year[9] - Total revenue for the first three quarters of 2022 was CNY 1,380,375,163.96, a decrease of 5.93% compared to CNY 1,467,782,116.49 in the same period of 2021[30] - Net profit for Q3 2022 was a loss of CNY 48,381,746.93, compared to a profit of CNY 47,910,931.43 in Q3 2021, indicating a significant decline[33] - The net profit attributable to the parent company was -$46.83 million, compared to a profit of $49.39 million in the same period last year, indicating a significant decline[37] - The total comprehensive income amounted to -$49.08 million, down from $32.77 million year-over-year[37] - The basic and diluted earnings per share were both -$0.066, compared to $0.069 in the previous year[39] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,823,823,724.11, an increase of 1.74% from the end of the previous year[9] - Total current assets as of September 30, 2022, amounted to RMB 2,739,426,823.28, an increase from RMB 2,684,319,610.62 as of December 31, 2021, reflecting a growth of approximately 2.05%[25] - Total liabilities reached CNY 1,975,015,526.92 in Q3 2022, up from CNY 1,881,410,098.21, reflecting an increase of 4.99%[30] - Non-current assets totaled CNY 1,084,396,900.83, slightly up from CNY 1,074,018,034.94, indicating a growth of 0.30%[30] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥161,602,511.28, indicating a significant decline in cash inflow[9] - Cash flow from operating activities generated a net outflow of -$161.60 million, a decrease from a net inflow of $291.74 million in the same period last year[39] - Cash inflow from investment activities was $272.08 million, up from $207.72 million year-over-year[42] - Cash flow from financing activities resulted in a net inflow of $179.50 million, compared to $111.62 million in the previous year[42] - The ending balance of cash and cash equivalents was $1.25 billion, an increase from $1.06 billion at the end of the previous year[42] Investments and Expenses - Research and development expenses for Q3 2022 amounted to CNY 22,237,239.07, an increase from CNY 18,244,320.92 in Q3 2021, representing a growth of 21.83%[33] - The company received government subsidies amounting to ¥247,424.64 during the quarter, primarily related to its pharmaceutical business[11] - The company received a total of RMB 298,534,345.93 in exit compensation from the Jiangsu Xiangshui Ecological Chemical Park Management Committee, out of a total compensation of RMB 384,555,277.93[21] Changes in Accounts - The company reported a 30.77% increase in prepaid accounts, attributed to increased procurement payments[14] - The company experienced a 723.27% increase in other receivables due to compensation payments from a subsidiary[14] - Accounts receivable increased to RMB 919,066,487.34 from RMB 759,968,112.40, representing a growth of approximately 20.93%[25] - Other receivables rose sharply to RMB 101,998,332.46 from RMB 12,389,438.11, marking an increase of around 726.5%[25] - The company reported a decrease in accounts payable from CNY 131,756,572.16 to CNY 105,173,460.43, a reduction of 20.29%[30] Equity and Ownership - The company’s total equity attributable to shareholders was ¥1,828,448,481.45, a decrease of 1.43% from the previous year[9] - The company’s weighted average return on equity was -1.51%, a decrease of 0.45 percentage points from the previous year[9] - There are no known related party transactions among the top shareholders, ensuring transparency in ownership structure[20] General Remarks - The company has not disclosed any significant new product developments or market expansions during the reporting period[21] - The company plans to continue focusing on R&D to drive future growth despite current losses[33]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥786,093,341.69, a decrease of 24.02% compared to ¥1,034,598,453.53 in the same period last year[23]. - The net profit attributable to shareholders for the first half of 2022 was -¥19,412,288.21, representing a decline of 127.89% from ¥69,603,017.12 in the previous year[23]. - The net cash flow from operating activities was -¥109,668,173.64, a significant drop from ¥494,509,740.72 in the same period last year, marking a decrease of 122.18%[23]. - The total assets at the end of the reporting period were ¥3,604,463,613.67, down 4.09% from ¥3,758,337,645.56 at the end of the previous year[23]. - The net assets attributable to shareholders at the end of the reporting period were ¥1,853,165,561.44, a slight decrease of 0.10% from ¥1,855,013,445.80 at the end of the previous year[23]. - The basic earnings per share for the first half of 2022 was -¥0.027, a decrease of 127.81% compared to ¥0.098 in the same period last year[24]. - The weighted average return on net assets was -1.052%, a decrease of 4.75 percentage points from 3.700% in the previous year[24]. - The decline in net profit was primarily due to the absence of asset disposal gains from the previous year, as the company completed the relocation of a subsidiary[25]. - The negative cash flow from operating activities was mainly attributed to a decline in sales revenue due to the pandemic, which affected cash receipts from sales[25]. Investments and Research - The company has made significant investments in R&D, with expenses amounting to CNY 15.71 million, an increase of 34.54% year-on-year[52]. - The company is advancing the development of the anti-tumor new drug YS001 capsule, which has been approved for Phase I clinical trials[50]. - The company established a joint laboratory for recombinant collagen medical devices in collaboration with Zhejiang University, aiming for market-oriented product development[51]. - The company is committed to building a systematic product development platform through technology introduction, investment, and independent research[32]. - The company is actively pursuing mergers and acquisitions to complement its pharmaceutical and medical beauty product lines, focusing on high-end generics and innovative drugs[29]. Market and Product Development - The pharmaceutical segment focuses on antiviral, immune regulation, anti-tumor, digestive system, and cardiovascular products, with key products including Abidol and Mesobam[29]. - The company aims to enhance its product matrix by focusing on non-surgical medical beauty products and has secured exclusive distribution rights for several high-end products from South Korea[32]. - The company has established a medical aesthetics division and launched a subsidiary in Hong Kong to expand its medical beauty strategy[29]. - The pharmaceutical industry in China saw a 0.60% year-on-year decline in revenue for the first half of 2022, totaling RMB 14,007.80 billion[33]. - The market size for hyaluronic acid-based dermal fillers in China was RMB 6.4 billion in 2021, with a CAGR of 19.7% from 2017 to 2021, and is projected to reach RMB 19.6 billion by 2026, reflecting a CAGR of 25.0% from 2021 to 2026[36]. - The market for polylactic acid-based dermal fillers in China is expected to grow significantly, with sales projected to reach RMB 1.82 billion by 2026, representing a CAGR of 74.9% from 2021 to 2026, and RMB 3.76 billion by 2030, with a CAGR of 19.9% from 2026 to 2030[37]. Financial Management and Risks - The company faces risks including industry policy changes, technological innovation risks, and customer credit risks, which may impact profitability[69]. - The company plans to enhance its innovation system and improve operational management to adapt to industry trends and mitigate risks[69]. - The company is focusing on strengthening credit transaction management and risk management training to reduce bad debt losses[71]. - The company is committed to improving production efficiency and resource allocation to address rising production costs and regulatory compliance[76]. - The company emphasizes the importance of financial risk management due to its reliance on short-term liabilities[78]. Environmental Compliance - The company reported a total COD discharge of 0.41 tons for the first half of the year, well below the annual limit of 7.62 tons, indicating compliance with pollution discharge standards[94]. - Total nitrogen discharge was recorded at 0.10 tons, significantly lower than the annual limit of 0.37 tons, demonstrating adherence to environmental regulations[94]. - The company has established effective waste gas treatment facilities, ensuring that all pollution discharge indicators meet the required standards[98]. - The company has successfully completed environmental impact assessments for all constructed projects and obtained necessary discharge permits[101]. - The company has implemented a self-monitoring plan for environmental compliance, with all pollutant discharge concentrations meeting national and local standards[103]. Corporate Governance - The company’s controlling shareholder, Suzhou Wuzhong Investment Holding Co., Ltd., committed to not engaging in business that competes with Jiangsu Wuzhong Industrial Co., Ltd. since December 28, 2009, with no fixed term for this commitment[109]. - The company reported that it will avoid related party transactions unless necessary, ensuring fair market pricing to protect the interests of Jiangsu Wuzhong Industrial Co., Ltd. and its shareholders[109]. - The company has made a commitment to maintain independence in governance and operations, separating its assets, personnel, finance, and business from its controlling shareholder since December 28, 2009[109]. - The company has pledged that funds raised from non-public stock issuance will not be used for real estate or related businesses, ensuring compliance with regulatory requirements since May 15, 2015[111]. - The company has committed to transparency in related party transactions, ensuring that any necessary transactions are conducted fairly and disclosed appropriately[111]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 78,199[129]. - The largest shareholder, Suzhou Wuzhong Investment Holding Co., Ltd., held 122,795,762 shares, representing 17.24% of total shares[129]. - The company issued 3,304,000 restricted stocks to 109 incentive targets as part of its 2021 incentive plan, converting these from unrestricted circulating shares[126]. - The total number of shares remained unchanged at 712,388,832 after the issuance of restricted stocks[126]. - The company has no preferred shareholders with restored voting rights as of the reporting date[129]. Legal and Regulatory Matters - There were no significant lawsuits or arbitration matters reported during the reporting period, indicating a stable legal standing for the company[114]. - The company and its controlling shareholders have maintained good integrity, with no court judgments unfulfilled or significant debts overdue[114]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties during the reporting period[112]. - The company has adhered to all commitments made regarding governance and operational independence, with no violations reported[111].

Financial Performance - The company's operating revenue for Q1 2022 was ¥444,334,210.73, representing a decrease of 18.42% compared to the same period last year[6]. - The net profit attributable to shareholders was ¥7,616,890.35, down 91.98% year-on-year[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥3,564,967.59, an increase of 147.52% compared to the previous year[6]. - Basic and diluted earnings per share were both ¥0.011, down 91.96% compared to the same period last year[9]. - Total operating revenue for Q1 2022 was CNY 444,334,210.73, down 18.4% from CNY 544,676,711.15 in Q1 2021[35]. - Net profit for Q1 2022 was CNY 7,016,937.24, a significant decline from CNY 94,976,017.36 in Q1 2021[35]. Cash Flow - The net cash flow from operating activities was ¥43,601,145.05, a decrease of 91.72% year-on-year[6]. - In Q1 2022, the net cash flow from operating activities was ¥43,601,145.05, a significant decrease of 91.7% compared to ¥526,509,617.96 in Q1 2021[41]. - Total cash inflow from investment activities was ¥86,880,669.00, down from ¥200,216,527.29 in the previous year, reflecting a decline of 56.7%[43]. - Cash inflow from financing activities totaled ¥572,340,828.62, an increase of 9.3% compared to ¥523,548,121.51 in Q1 2021[43]. - The total cash and cash equivalents at the end of Q1 2022 stood at ¥1,337,683,178.90, slightly down from ¥1,390,736,406.74 at the end of Q1 2021[43]. - Cash received from sales and services in Q1 2022 was ¥1,529,661,484.00, a decrease of 25.4% from ¥2,053,130,900.71 in Q1 2021[41]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,704,724,379.12, a decrease of 1.43% from the end of the previous year[9]. - The total current assets as of March 31, 2022, were RMB 2,634,823,944.40, slightly down from RMB 2,684,319,610.62 at the end of 2021, reflecting a decrease of approximately 1.8%[26]. - The company's non-current assets totaled RMB 1,069,900,434.72 as of March 31, 2022, compared to RMB 1,074,018,034.94 at the end of 2021, showing a decrease of about 0.4%[26]. - Total liabilities decreased to CNY 1,806,471,158.74 in Q1 2022 from CNY 1,881,410,098.21 in Q1 2021, a reduction of 4.0%[31]. - Total equity increased to CNY 1,898,253,220.38 in Q1 2022 from CNY 1,876,927,547.35 in Q1 2021, an increase of 1.1%[31]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 76,000[14]. - The largest shareholder, Suzhou Wuzhong Investment Holding Co., Ltd., held 17.24% of the shares, with 92,900,000 shares pledged[14]. Research and Development - The company increased its R&D expenses by 332.17% during the reporting period[13]. - Research and development expenses increased to CNY 8,136,954.52 in Q1 2022, compared to CNY 1,882,812.81 in Q1 2021, reflecting a growth of 331.5%[35]. Other Financial Metrics - The return on equity (ROE) was 0.41%, down 4.60% year-on-year[9]. - Financial expenses rose to CNY 19,308,006.66 in Q1 2022, compared to CNY 18,417,168.13 in Q1 2021, an increase of 4.8%[35]. - The company's retained earnings showed a slight improvement, with a deficit of CNY -332,797,898.60 in Q1 2022 compared to CNY -340,414,788.95 in Q1 2021[31]. Investments and Subsidiaries - The company established a wholly-owned subsidiary in Hong Kong with a registered capital of USD 1 million during the reporting period[20]. - The company’s investment in Hangzhou Lingjian Medical Technology Partnership increased by RMB 6.8 million, raising the total contribution to RMB 117.2 million[21].

Financial Performance - The company's operating revenue for Q3 2021 was ¥433,183,662.96, representing a year-on-year increase of 19.79%[7] - The net profit attributable to shareholders for Q3 2021 was -¥20,214,303.68, showing a year-on-year increase of 26.10%[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥31,411,778.89, a decrease of 19.82% compared to the same period last year[7] - Total revenue for the first three quarters of 2021 was RMB 1,467,782,116.49, a decrease of 0.08% compared to RMB 1,480,902,752.55 in the same period of 2020[29] - The company reported a net loss of RMB 285,970,839.39 for the first three quarters of 2021, an improvement from a loss of RMB 335,359,552.83 in the same period of 2020[29] - Total revenue for Q3 2021 was 61,630,273.78, a significant recovery from a loss of 43,895,401.68 in Q3 2020[36] - Net profit for Q3 2021 reached 47,910,931.43, compared to a net loss of 46,885,237.77 in the same period last year[36] - The company reported a total comprehensive income of 32,796,452.79 for Q3 2021, compared to a loss of 46,885,237.77 in Q3 2020[36] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date was ¥291,744,712.10, reflecting a significant increase of 393.79%[10] - Cash flow from operating activities for the first nine months of 2021 was 291,744,712.10, a recovery from a negative cash flow of -99,303,646.06 in the same period last year[38] - Cash inflow from investment activities totaled $207,719,660.60, a significant increase from $80,779,263.04[41] - Cash outflow from investment activities amounted to $198,894,773.23, compared to $69,751,376.20 in the previous period[41] - Net cash flow from investment activities was $8,824,887.37, down from $11,027,886.84[41] - Cash inflow from financing activities reached $1,208,990,674.64, compared to $1,436,656,652.08 previously[41] - Cash outflow from financing activities was $1,097,372,527.19, slightly higher than $1,046,497,726.24 last period[41] - Net cash flow from financing activities was $111,618,147.45, a decrease from $390,158,925.84[41] - The net increase in cash and cash equivalents was $412,184,763.79, compared to $301,881,300.89 previously[41] - The ending balance of cash and cash equivalents was $1,057,795,264.03, up from $890,495,959.37[41] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,864,695,658.79, an increase of 4.35% compared to the end of the previous year[10] - As of September 30, 2021, current assets totaled RMB 2,801,549,643.26, an increase of 4.52% from RMB 2,680,113,063.65 at the end of 2020[24] - Total liabilities as of September 30, 2021, were RMB 1,967,558,613.96, compared to RMB 1,851,875,953.69 at the end of 2020, reflecting an increase of 6.25%[29] - The total assets as of September 30, 2021, were RMB 3,864,695,658.79, up from RMB 3,703,715,674.65 at the end of 2020, indicating an increase of 4.34%[29] Shareholder Information - The equity attributable to shareholders at the end of the reporting period was ¥1,882,124,551.14, up 1.85% from the end of the previous year[10] - The company had a total of 85,650 common shareholders at the end of the reporting period[17] Research and Development - Research and development expenses increased to 18,244,320.92, up from 13,975,268.79 in Q3 2020, indicating a focus on innovation[36] - Government subsidies recognized during the reporting period amounted to ¥12,293,635.05, primarily related to drug research and development[10] Other Income and Expenses - Other income for Q3 2021 was 16,849,123.10, significantly higher than 8,318,607.63 in Q3 2020, indicating improved financial performance[32] - Sales expenses decreased to 323,378,635.79 from 341,694,207.32 in Q3 2020, reflecting cost management efforts[32] - Total operating costs for Q3 2021 were 1,543,593,828.16, slightly down from 1,548,280,482.83 in Q3 2020[32] Asset Disposal and Compensation - The company recognized asset disposal gains from the completion of relocation procedures for its subsidiary, contributing to the significant increase in net profit[13] - The company received a total of RMB 384,555,277.93 in compensation from the Jiangsu Xiangshui Ecological Chemical Park Management Committee[21] - The company has received RMB 125,034,345.93 in exit compensation as of the report date[21] Investments - Long-term equity investments increased to RMB 489,915,297.50 from RMB 394,923,331.51, showing a growth of 24.06%[24] - Cash received from other investment activities was $190,030,009.24, significantly higher than $40,000,000.00[41] - Cash paid for investments totaled $95,000,000.00, compared to $10,000,000.00 in the previous period[41]

Financial Performance - The company's operating revenue for the first half of 2021 was ¥1,034,598,453.53, a decrease of 7.57% compared to the same period last year[23]. - The net profit attributable to shareholders of the listed company was ¥69,603,017.12, a significant recovery from a loss of ¥18,609,373.28 in the previous year[23]. - The net cash flow from operating activities increased to ¥494,509,740.72, compared to a negative cash flow of ¥70,545,729.30 in the same period last year[23]. - The total assets at the end of the reporting period were ¥3,798,895,089.88, reflecting a 2.57% increase from the end of the previous year[23]. - The net assets attributable to shareholders of the listed company increased by 3.78% to ¥1,917,688,170.15 compared to the end of the previous year[23]. - The basic earnings per share for the first half of 2021 was ¥0.098, a recovery from a loss of ¥0.026 per share in the same period last year[23]. - The weighted average return on net assets was 3.70%, an increase of 4.49 percentage points compared to the previous year[23]. - The significant increase in net profit was primarily due to the asset disposal gains from the completion of the relocation of the Zhongkai Biological Pharmaceutical Plant[24]. - The increase in net cash flow from operating activities was mainly attributed to a substantial rise in cash received from sales of goods[24]. - The company reported non-operating income of approximately ¥97.39 million, primarily from non-current asset disposal gains of ¥100.63 million and government subsidies of ¥10.28 million[25]. Market and Product Development - The pharmaceutical sector focuses on antiviral, immune regulation, anti-tumor, digestive system, and cardiovascular products, with key products including Abidol and Trimetazidine, which have been included in national medical insurance directories[29]. - The company has established a medical beauty division and strategically controls Chengdu Shangli Huimei Biotechnology Co., which holds exclusive rights for a new hyaluronic acid product in China[32]. - The medical beauty market in China is rapidly growing, with the hyaluronic acid market expected to reach ¥6.56 billion in 2021, up from ¥5.11 billion in 2020[37]. - The company aims to enhance its core competitiveness by focusing on high-end generic drugs, innovative drug development, and expanding its product pipeline[29]. - The pharmaceutical manufacturing industry in China achieved a revenue of ¥1.40 trillion in the first half of 2021, reflecting a year-on-year growth rate of 28%[33]. - The company is actively pursuing mergers and acquisitions in the non-surgical medical beauty sector to expand its product offerings and market presence[29]. - The company has received clinical trial approval for its innovative cancer treatment drug YS001, which is set to enter phase I clinical research[29]. - The company operates through various sales channels, including agents, medical institutions, and retail pharmacies, ensuring a comprehensive distribution network[32]. - The company has undergone a name and business scope change to align with its strategic focus on the pharmaceutical and medical beauty industries[29]. Research and Development - The company has established a complete industrial chain covering gene drugs, chemical drugs, and modern traditional Chinese medicine, supported by multiple research institutions[39]. - The company has completed research submissions for several key projects, including the consistency evaluation of various drugs, which are currently under review by the National Medical Products Administration[44]. - The company’s R&D expenses increased by 8.02% to CNY 11.68 million, compared to CNY 10.81 million in the previous year[48]. - The company plans to enhance its R&D capabilities and market strategies to improve product competitiveness and market share[70]. Environmental Compliance - The company’s Suzhou pharmaceutical plant was listed as a key pollutant discharge unit, with specific emissions data reported[86]. - Total COD emissions from the Suzhou plant were 1.99 tons for the first half of 2021, well below the annual limit of 7.62 tons[86]. - The company is focused on maintaining compliance with environmental standards, with all reported emissions within acceptable limits[86]. - The company has established a wastewater treatment facility with a capacity of 150m³/d, which includes a pre-treatment system that significantly reduces pollutant levels in wastewater[92]. - All pollution discharge indicators are compliant with the relevant standards, including the Pharmaceutical Industry Air Pollutant Emission Standards and the Chemical Industry Volatile Organic Compounds Emission Standards[92]. - The company has a total of over 500 square meters of hazardous waste storage facilities, which are equipped with anti-corrosion and leak-proof measures[92]. - The company has implemented an online monitoring system for wastewater, measuring parameters such as flow, pH, COD, ammonia nitrogen, total phosphorus, and total nitrogen[97]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[98]. - The company has not experienced any significant environmental incidents or accidents since commencing production[98]. - The company has a robust VOCs leakage detection and remediation plan in place to effectively reduce VOC emissions[92]. Corporate Governance and Shareholder Relations - The controlling shareholder, Suzhou Wuzhong Investment Holding Co., Ltd., committed to not engaging in business that competes with Jiangsu Wuzhong Industrial Co., Ltd. since December 28, 2009, with no fixed term for the commitment[103]. - The company has ensured that any related transactions with Jiangsu Wuzhong Industrial Co., Ltd. will be conducted at market prices to protect the interests of the company and its shareholders[103]. - The commitment to maintain independence in governance and operations from the controlling shareholder was made on December 28, 2009, with no fixed term[103]. - The controlling parties, including Hangzhou Fuhui Industrial Co., Ltd., have committed to avoiding substantial competition with the listed company and will not invest in similar products since February 2, 2018, with no fixed term[103]. - The company has committed to not using raised funds for real estate or related businesses, ensuring that funds will only be used for operational needs in the pharmaceutical sector since May 15, 2015, with no fixed term[106]. - The number of ordinary shareholders at the end of the reporting period is 85,002[119]. - The largest shareholder, Suzhou Wuzhong Investment Holding Co., Ltd., holds 122,795,762 shares, accounting for 17.24% of the total shares[120]. - The second-largest shareholder, Zhu Yi, holds 16,512,430 shares, accounting for 2.32% of the total shares[120]. - The company has not disclosed any major contracts or significant related party transactions during the reporting period[116]. - There are no overdue guarantees or significant impacts on the company's financial results from related party debts[116]. Financial Position and Liabilities - The total liabilities were reported at ¥1,873,811,991.16, compared to ¥1,851,875,953.69 in the previous period[136]. - The company's total assets reached CNY 2,913,780,138.08, up from CNY 2,814,921,980.51, marking an increase of approximately 3.51%[143]. - The total owner's equity amounted to ¥1,925,083,098.72, compared to ¥1,851,839,720.96 previously[136]. - The company reported a net loss of ¥265,756,535.71 in retained earnings, an improvement from a loss of ¥335,359,552.83[136]. - The total current liabilities were ¥1,632,073,831.14, slightly up from ¥1,595,291,392.94[134]. - The company’s inventory decreased to ¥131,127,052.29 from ¥154,819,292.98[131]. - The total amount of guarantees provided to debtors with an asset-liability ratio exceeding 70% is 12,500.00 million RMB[116]. - The total amount of guarantees exceeding 50% of net assets is 4,955.59 million RMB[116]. - The company provided a total of 68,000.00 million RMB in guarantees to subsidiaries during the reporting period[116]. Share Capital and Stock Management - The company has a registered capital of RMB 712,388,832.00 and a total share capital of 712,388,832 shares, with each share having a par value of RMB 1[189]. - The company’s stock was listed on the Shanghai Stock Exchange on April 1, 1999, following its establishment in 1994[189]. - The company has implemented a stock incentive plan, with a total of 4,900,000 restricted shares granted to 27 incentive objects in 2015[189]. - The company has undergone several capital adjustments and approvals from the China Securities Regulatory Commission for its stock issuance and incentive plans[189]. - The company has not reported any new capital contributions or significant changes in equity instruments during the current period[173]. - The total capital reserve increased slightly from the previous period, indicating some retained earnings were allocated to reserves[186]. - The company has maintained its capital structure with no new equity instruments issued during the reporting period[186].

Financial Performance - In 2020, the company reported a total operating revenue of CNY 1,871,736,670.77, a decrease of 11.29% compared to CNY 2,109,850,652.89 in 2019[26] - The net profit attributable to shareholders of the listed company was CNY -506,410,725.69, representing a significant decline of 884.72% from CNY 64,533,748.49 in the previous year[26] - The net cash flow from operating activities was CNY -414,558,357.17, worsening from CNY -166,027,875.30 in 2019[26] - As of the end of 2020, the net assets attributable to shareholders of the listed company were CNY 1,847,850,316.34, a decrease of 21.64% from CNY 2,358,139,574.02 at the end of 2019[26] - Total assets at the end of 2020 were CNY 3,703,715,674.65, down 5.52% from CNY 3,919,919,292.37 in 2019[26] - The company did not propose any profit distribution or capital reserve transfer to increase share capital for 2020 due to the net loss incurred[7] - The company’s net profit after deducting non-recurring gains and losses was CNY -163,068,617.18, compared to CNY -72,152,971.71 in 2019[26] - Basic earnings per share for 2020 was -0.711 yuan, a decrease of 890.00% compared to 2019[28] - The net profit attributable to shareholders decreased significantly in 2020 due to large asset impairment provisions and a decline in pharmaceutical sales caused by the COVID-19 pandemic[28] Industry Context - The company faced significant industry risks as outlined in the report, which may impact future performance[8] - In 2020, the pharmaceutical manufacturing industry achieved a total revenue of 2,485.73 billion RMB, representing a year-on-year growth of 4.50%[44] - The overall pharmaceutical industry is recovering from the impact of COVID-19, with ongoing reforms in medical insurance and procurement policies enhancing the industry's resilience[153] - The pharmaceutical industry is experiencing a "micro-profit" era, leading to increased market risks and operational pressures for mid-sized companies like Wu Zhong Medicine[169] Research and Development - The company is focusing on high-end generic drugs, innovative drug development, and has initiated research on a new cancer treatment drug in collaboration with Zhejiang University[40] - The company has established a robust R&D infrastructure, including provincial-level technology centers and a team of expert consultants[50] - The total R&D investment amounted to CNY 26,761,866.04, accounting for 1.43% of total revenue, with 104 R&D personnel, making up 7.87% of the total workforce[70] - The company is actively pursuing strategic partnerships and collaborations with universities and research institutions to strengthen its R&D capabilities[56] - The company is focusing on expanding its pharmaceutical health industry chain through strategic investments and mergers and acquisitions[43] - The company is advancing multiple R&D projects, including the completion of clinical efficacy studies for the drug Pidotimod Oral Solution, which is aimed at treating recurrent respiratory infections[109] - The company aims to expand its product offerings and improve market competitiveness through newly approved products[116] - The company is focusing on acquiring high-quality resources for mergers and acquisitions to build a medical beauty operation platform[165] Sales and Marketing - The company established four new departments to enhance its marketing system, focusing on online and offline sales channels[56] - The company primarily utilized self-operated terminal sales, distribution, and e-commerce models for sales channels[127] - The main customer region was Jiangsu Province, contributing 40% of the revenue, followed by Xinjiang and Henan provinces[132] - The pricing strategy for major drugs is based on competitive bidding and provincial centralized procurement, which may affect future profitability[134] - The company is implementing a new marketing incentive policy to establish a high-quality nationwide marketing network[159] Financial Management and Governance - The company maintains a stable profit distribution policy, committing to a minimum cash dividend of 20% of distributable profits when conditions are met[176] - The company’s cash dividend policy requires a minimum cash dividend ratio of 30% of the net profit attributable to shareholders, which was not met in 2020[179] - The board of directors' proposal for profit distribution must be approved by more than two-thirds of the voting rights at the shareholders' meeting[179] - The company has committed to avoiding competition with its controlling shareholder and ensuring fair transactions in related party dealings[185] - The company has engaged Zhonghui Accounting Firm for the audit of its 2020 financial report, with an audit fee of 1.5 million RMB[195] Operational Challenges - The company faces challenges compared to leading enterprises in the Chinese pharmaceutical manufacturing industry in terms of overall scale, product scale, asset scale, and R&D capabilities[89] - The introduction of new policies like "4+7 volume-based procurement" poses higher challenges to the company's marketing strategies[89] - The company is currently undergoing multiple product evaluations at the NMPA review center, with potential risks of non-compliance during clinical trials impacting business[168] - The company faces significant policy risks due to increased government regulation in the pharmaceutical industry, particularly with volume-based procurement and local medical insurance directory cancellations[166] Social Responsibility - The company actively engaged in social responsibility during the COVID-19 pandemic, supplying 100,000 boxes of Abidol tablets to Hubei province and making donations for epidemic prevention[52]